Over the last couple of months various members of the PROFILE Consortium have published several new results from their research:
- Prof. Karen Vanhoorelbeke and her laboratory at KU Leuven researched the pre-clinical efficacy of a widely used and worldwide approved mucolytic agent, N-Acetylcysteine, in prevention and treatment of signs and symptoms of Thrombotic Thrombocytopenic Purpura (TTP) in animal models of the disease. The article was published on Blood journal (link here);
- Prof. Agnes Veyradier and Alain Stepanian from AP-HP CNR-MAT published research regarding the usefullness of ADAMTS13 and von Willebrand Factor in predicting blood clotting complications (venous thromboembolism) in patients with cancer. The article was published on the Journal of Thrombosis and Haemostasis (link here);
- Prof. Agnes Veyradier*, Karen Vanhoorelbeke** and Berangere Joly* (*AP-HP CNR-MAT and **KU Leuven) published a summarized review of the current and future therapeutic targets in Thrombotic Thrombocytopenic Purpura. It was published in the journal Intensive Care Medicine (link here);
- Prof. Paul Coppo, from AP-HP CNR-MAT published a detailed summary of how autoimmune Thrombotic Thrombocitopenic Purpura is treated, in the journal Transfusion and Apheresis Science (link here);
- Prof. Agnes Veyradier and Paul Coppo (AP-HP CNR-MAT), together with a network of French collaborators from Hospitals of the entire French territory have published on the difficulties for diagnosing and reasons for misdiagnosing the clinically-challenging TTP according to the French Thrombotic Microangiopathies Reference Center (CNR-MAT) experience. The study was published in the American Journal of Hematology (link here).
More news soon! 🙂